Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$4.9 million.

  • Lyell Immunopharma's Non Operating Income fell 18205.0% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 650.57%. This contributed to the annual value of $15.8 million for FY2024, which is 2735.13% up from last year.
  • Latest data reveals that Lyell Immunopharma reported Non Operating Income of -$4.9 million as of Q3 2025, which was down 18205.0% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Non Operating Income registered a high of $9.2 million during Q4 2024, and its lowest value of -$36.2 million during Q4 2021.
  • Over the past 5 years, Lyell Immunopharma's median Non Operating Income value was $938000.0 (recorded in 2022), while the average stood at $73842.1.
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 92142.86% in 2021, then tumbled by 143461.54% in 2022.
  • Lyell Immunopharma's Non Operating Income (Quarter) stood at -$36.2 million in 2021, then soared by 117.66% to $6.4 million in 2022, then grew by 2.99% to $6.6 million in 2023, then soared by 40.04% to $9.2 million in 2024, then crashed by 152.75% to -$4.9 million in 2025.
  • Its Non Operating Income was -$4.9 million in Q3 2025, compared to $4.5 million in Q2 2025 and $5.2 million in Q1 2025.